These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 19505922)

  • 21. MicroRNA expression profiling of exfoliated colonocytes isolated from feces for colorectal cancer screening.
    Koga Y; Yasunaga M; Takahashi A; Kuroda J; Moriya Y; Akasu T; Fujita S; Yamamoto S; Baba H; Matsumura Y
    Cancer Prev Res (Phila); 2010 Nov; 3(11):1435-42. PubMed ID: 20959518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospective evaluation of fecal calprotectin as a screening biomarker for colorectal neoplasia.
    Limburg PJ; Devens ME; Harrington JJ; Diehl NN; Mahoney DW; Ahlquist DA
    Am J Gastroenterol; 2003 Oct; 98(10):2299-305. PubMed ID: 14572583
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Fecal oncomarkers in the diagnostics of colorectal cancer].
    Mikhaĭlova EI; Pimanov SI; Voropaev EV
    Klin Med (Mosk); 2007; 85(12):62-7. PubMed ID: 18318171
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship between tumor and plasma levels of hTERT mRNA in patients with colorectal cancer: implications for monitoring of neoplastic disease.
    Terrin L; Rampazzo E; Pucciarelli S; Agostini M; Bertorelle R; Esposito G; DelBianco P; Nitti D; De Rossi A
    Clin Cancer Res; 2008 Nov; 14(22):7444-51. PubMed ID: 19010861
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gastrointestinal tract cancer screening using fecal carcinoembryonic antigen.
    Kim Y; Lee S; Park S; Jeon H; Lee W; Kim JK; Cho M; Kim M; Lim J; Kang CS; Han K
    Ann Clin Lab Sci; 2003; 33(1):32-8. PubMed ID: 12661896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cumulative evaluation of a quantitative immunochemical fecal occult blood test to determine its optimal clinical use.
    Rozen P; Comaneshter D; Levi Z; Hazazi R; Vilkin A; Maoz E; Birkenfeld S; Niv Y
    Cancer; 2010 May; 116(9):2115-25. PubMed ID: 20186820
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia.
    Smith A; Young GP; Cole SR; Bampton P
    Cancer; 2006 Nov; 107(9):2152-9. PubMed ID: 16998938
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia.
    de Wijkerslooth TR; Stoop EM; Bossuyt PM; Meijer GA; van Ballegooijen M; van Roon AH; Stegeman I; Kraaijenhagen RA; Fockens P; van Leerdam ME; Dekker E; Kuipers EJ
    Am J Gastroenterol; 2012 Oct; 107(10):1570-8. PubMed ID: 22850431
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fecal pyruvate kinase-M2 (tumor M2-PK) measurement: a new screening concept for colorectal cancer.
    Ewald N; Schaller M; Bayer M; Akinci A; Bretzel RG; Kloer HU; Hardt PD
    Anticancer Res; 2007; 27(4A):1949-52. PubMed ID: 17649802
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Testing of multiple samples increases the sensitivity of stool decay-accelerating factor test for the detection of colorectal cancer.
    Mizuno M; Mizuno M; Iwagaki N; Nasu J; Okazaki H; Yamamoto K; Okada H; Tsuji T; Fujita T; Shiratori Y
    Am J Gastroenterol; 2003 Nov; 98(11):2550-5. PubMed ID: 14638362
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Pyruvate kinase M2 (tumor M2-PK) as a screening tool for colorectal cancer (CRC). A review of current published data].
    Ewald N; Toepler M; Akinci A; Kloer HU; Bretzel RG; Hardt PD
    Z Gastroenterol; 2005 Dec; 43(12):1313-7. PubMed ID: 16315127
    [TBL] [Abstract][Full Text] [Related]  

  • 32. E1A-F is overexpressed early in human colorectal neoplasia and associated with cyclooxygenase-2 and matrix metalloproteinase-7.
    Boedefeld WM; Soong R; Weiss H; Diasio RB; Urist MM; Bland KI; Heslin MJ
    Mol Carcinog; 2005 May; 43(1):13-7. PubMed ID: 15800927
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fecal miR-106a is a useful marker for colorectal cancer patients with false-negative results in immunochemical fecal occult blood test.
    Koga Y; Yamazaki N; Yamamoto Y; Yamamoto S; Saito N; Kakugawa Y; Otake Y; Matsumoto M; Matsumura Y
    Cancer Epidemiol Biomarkers Prev; 2013 Oct; 22(10):1844-52. PubMed ID: 23950216
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of a selective screening for colorectal carcinoma: the Taiwan Multicenter Cancer Screening (TAMCAS) project.
    Chen TH; Yen MF; Lai MS; Koong SL; Wang CY; Wong JM; Prevost TC; Duffy SW
    Cancer; 1999 Oct; 86(7):1116-28. PubMed ID: 10506694
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A validated quantitative assay to detect occult micrometastases by reverse transcriptase-polymerase chain reaction of guanylyl cyclase C in patients with colorectal cancer.
    Schulz S; Hyslop T; Haaf J; Bonaccorso C; Nielsen K; Witek ME; Birbe R; Palazzo J; Weinberg D; Waldman SA
    Clin Cancer Res; 2006 Aug; 12(15):4545-52. PubMed ID: 16899600
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene.
    Chen WD; Han ZJ; Skoletsky J; Olson J; Sah J; Myeroff L; Platzer P; Lu S; Dawson D; Willis J; Pretlow TP; Lutterbaugh J; Kasturi L; Willson JK; Rao JS; Shuber A; Markowitz SD
    J Natl Cancer Inst; 2005 Aug; 97(15):1124-32. PubMed ID: 16077070
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gene expression analysis using a highly sensitive DNA microarray for colorectal cancer screening.
    Koga Y; Yamazaki N; Takizawa S; Kawauchi J; Nomura O; Yamamoto S; Saito N; Kakugawa Y; Otake Y; Matsumoto M; Matsumura Y
    Anticancer Res; 2014 Jan; 34(1):169-76. PubMed ID: 24403458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Colon cancer screening strategies.
    Agrawal J; Syngal S
    Curr Opin Gastroenterol; 2005 Jan; 21(1):59-63. PubMed ID: 15687886
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of survivin-expressing circulating cancer cells (CCCs) in peripheral blood of patients with gastric and colorectal cancer reveals high risks of relapse.
    Yie SM; Lou B; Ye SR; Cao M; He X; Li P; Hu K; Rao L; Wu SM; Xiao HB; Gao E
    Ann Surg Oncol; 2008 Nov; 15(11):3073-82. PubMed ID: 18670822
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Evaluation of usefulness of faecal occult blood test. Prospective screening study in patients with colorectal neoplasia].
    Banaszkiewicz Z; Jawień A; Jarmocik P; Tojek K; Jankowski M; Switoński M
    Pol Merkur Lekarski; 2004 Dec; 17(102):579-82. PubMed ID: 15771126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.